Abstract
Ideally, the intraperitoneal chemotherapy (IP) delivery device is placed at the time of the original diagnostic procedure, when an optimal surgical resection can be completed. The patient, who is appropriately counseled before surgery about her risk of cancer and the treatment options available, should have an IP device placed at the time of surgical resection of the presumed ovarian or primary peritoneal cancer. The pathologic diagnosis and stage is not completely understood in that setting, but good clinical judgment can identify an appropriate candidate for IP chemotherapy. It is safer to place the device and remove it unused at the bedside later, than to forego placement and have to reoperate to place the device at a second procedure. The second procedure to place an IP catheter is an important barrier to initiating IP chemotherapy, and also delays proper treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pfeifle CE, Howell SB, Markman M, et al. Totally implantable system for peritoneal access. J Clin Oncol 1984;1(2):1277–1280.
Dedrick RL, Myers CE, Bungay PR, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62(1):1–11.
Pfeiffer P, Asmussen L, Kvist-Poulsen H, et al. Intraperitoneal chemotherapy: introduction of a new “single use” delivery system—A preliminary report. Gynecol Oncol 1989;35:47–49.
Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device. Tran Am Soc Artif Intern Organs 1968;V-14:181–187.
Piccart MJ, Speyer JL, Markman M, et al. Intraperitoneal chemotherapy: Technical experience at five institutions. Semin Oncol 1985;Vol XII(3) Suppl 4:90–96.
Myers CE, Collins JM. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1983;1(5):395–407.
Runowicz CD, Dottino PR, Shafir MK, et al. Catheter complications associated with intraperitoneal chemotherapy. Gynecol Oncol 1984;24:41–50.
Leehey DJ, Daugridas JT, INg TS, et al. The case against the “temporary” intraperitoneal catheter. Int J Artif Organs 1982;5:334–335.
Waggoner SE, Johnson J, Barter J, et al Intraperitoneal therapy administered through a groshong catheter. Gynecol Oncol 1994;53:320–325.
Braly P, Doroshow J, Hoff S. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Gynecol Oncol 1986;25:319–333.
Malmstrom H, Carstensen J, Simonsen E. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 1994;54:27–34.
Rubin SC, Hoskins WJ, Markman M, et al. Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecol Oncol 1989;33:46–48.
Orsi F, Vigna PD, Penco S, et al. Percutaneous placement of peritoneal port-catheter in oncologic patients. Eur Radiol 2004;14:2020–2024.
Sakuragi N, Nakajima A, Nomura E, et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol 2000;79:420–423.
Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 2001;81:77–81.
Davidson SA, Rubin SC, Markman M, et al. Intraperitoneal chemotherapy: Analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 1991;41:101–106.
Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A gynecologic oncology group study. Gynecol Oncol 2006;100:27–32.
Anaf V, Gangji D, Simon P, Saylam K. Laparoscopic insertion of intraperitoneal catheters for intraperitoneal chemotherapy. Acta Obstet Gynecol Scand 2003;82:1140–1145.
Van Dam PA, De Cloedt J, Tjalma WAA, Buyaert P, Becquart D, Vergote I, et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? Am J Obstet Gynecol 1999;181:536–541.
Arts HJG, Willern PHB, Tinga DJ, et al. Laparoscopic placement of PAP catheters of intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 1998;69:32–57.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Walker, J.L. (2007). Intraperitoneal Chemotherapy: Technique and Complications. In: Helm, C.W., Edwards, R.P. (eds) Intraperitoneal Cancer Therapy. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-195-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-59745-195-6_5
Publisher Name: Humana Press
Print ISBN: 978-1-58829-878-2
Online ISBN: 978-1-59745-195-6
eBook Packages: MedicineMedicine (R0)